Investment analysis and risk management in pharmaceutical companies

Mustafa Özyeşil; Havane Tembelo

Makale detayları

Investment analysis and risk management in pharmaceutical companies

Yazarlar:

Mustafa Özyeşil | Havane Tembelo

Yayıncı:

Istanbul University

Ana Başlıklar:

Pharmacy Management

Dergi:

İstanbul Journal of Pharmacy Vol.55 Issue 1, pp.10-18

Belge Tipi:

Makale

Yayın Tarihi:

7/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001353993

pISSN:

2587-2087

Anahtar kelimeler:

Özet:

 Background and Aims: The pharmaceutical industry, which is known for its high levels of innovation and substantial research and development efforts, is crucial for global healthcare advancement. Developing new drugs requires significant RD investments, which involve high levels of uncertainty and high costs. This study analyzes the investment strategies and risk management practises of leading pharmaceutical companies, Pfizer and Novartis. Methods: Financial performance indicators, investment trends, and risk mitigation techniques for Pfizer and Novartis were examined. The analysis focused on how these companies balance innovation with mitigating risks through substantial RD investments. Results: This study found that significant RD investments drive revenue growth, profitability, and stock prices. Specifically, 67.7 of the variability in revenue, 70.9 of the variability in net profit margin, and 48.3 of the variability in stock price growth are attributed to RD expenditures. Conclusion: These findings highlight the critical role of continuous innovation and strategic investment in maintaining a competitive advantage and financial health in the pharmaceutical industry. RD investments are essential for driving revenue growth, enhancing profitability, and boosting stock prices, underscoring the need for strategic risk management practises.

 Background and Aims: The pharmaceutical industry, which is known for its high levels of innovation and substantial research and development efforts, is crucial for global healthcare advancement. Developing new drugs requires significant RD investments, which involve high levels of uncertainty and high costs. This study analyzes the investment strategies and risk management practises of leading pharmaceutical companies, Pfizer and Novartis. Methods: Financial performance indicators, investment trends, and risk mitigation techniques for Pfizer and Novartis were examined. The analysis focused on how these companies balance innovation with mitigating risks through substantial RD investments. Results: This study found that significant RD investments drive revenue growth, profitability, and stock prices. Specifically, 67.7 of the variability in revenue, 70.9 of the variability in net profit margin, and 48.3 of the variability in stock price growth are attributed to RD expenditures. Conclusion: These findings highlight the critical role of continuous innovation and strategic investment in maintaining a competitive advantage and financial health in the pharmaceutical industry. RD investments are essential for driving revenue growth, enhancing profitability, and boosting stock prices, underscoring the need for strategic risk management practises.

 Background and Aims: The pharmaceutical industry, which is known for its high levels of innovation and substantial research and development efforts, is crucial for global healthcare advancement. Developing new drugs requires significant RD investments, which involve high levels of uncertainty and high costs. This study analyzes the investment strategies and risk management practises of leading pharmaceutical companies, Pfizer and Novartis. Methods: Financial performance indicators, investment trends, and risk mitigation techniques for Pfizer and Novartis were examined. The analysis focused on how these companies balance innovation with mitigating risks through substantial RD investments. Results: This study found that significant RD investments drive revenue growth, profitability, and stock prices. Specifically, 67.7 of the variability in revenue, 70.9 of the variability in net profit margin, and 48.3 of the variability in stock price growth are attributed to RD expenditures. Conclusion: These findings highlight the critical role of continuous innovation and strategic investment in maintaining a competitive advantage and financial health in the pharmaceutical industry. RD investments are essential for driving revenue growth, enhancing profitability, and boosting stock prices, underscoring the need for strategic risk management practises.

 Background and Aims: The pharmaceutical industry, which is known for its high levels of innovation and substantial research and development efforts, is crucial for global healthcare advancement. Developing new drugs requires significant RD investments, which involve high levels of uncertainty and high costs. This study analyzes the investment strategies and risk management practises of leading pharmaceutical companies, Pfizer and Novartis. Methods: Financial performance indicators, investment trends, and risk mitigation techniques for Pfizer and Novartis were examined. The analysis focused on how these companies balance innovation with mitigating risks through substantial RD investments. Results: This study found that significant RD investments drive revenue growth, profitability, and stock prices. Specifically, 67.7 of the variability in revenue, 70.9 of the variability in net profit margin, and 48.3 of the variability in stock price growth are attributed to RD expenditures. Conclusion: These findings highlight the critical role of continuous innovation and strategic investment in maintaining a competitive advantage and financial health in the pharmaceutical industry. RD investments are essential for driving revenue growth, enhancing profitability, and boosting stock prices, underscoring the need for strategic risk management practises.

Makale detayları

Investment analysis and risk management in pharmaceutical companies

Yazarlar:

Mustafa Özyeşil | Havane Tembelo

Yayıncı:

Istanbul University

Ana Başlıklar:

Pharmacy Management

Dergi:

İstanbul Journal of Pharmacy Vol.55 Issue 1, pp.10-18

Belge Tipi:

Makale

Yayın Tarihi:

7/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001353993

pISSN:

2587-2087

Pharmaceutical Industry

R&D Investment

Financial Performance

Risk Management

Innovation

Sayı

Makale detayları

Investment analysis and risk management in pharmaceutical companies

Yazarlar: Mustafa Özyeşil | Havane Tembelo

Yayıncı: Istanbul University

Ana Başlıklar: Pharmacy Management

Dergi: İstanbul Journal of Pharmacy Vol.55 Issue 1, pp.10-18

Belge Tipi: Makale

Yayın Tarihi: 7/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001353993

pISSN: 2587-2087

Pharmaceutical Industry

R&D Investment

Financial Performance

Risk Management

Innovation

Sayı

Yazarlar:

Mustafa Özyeşil | Havane Tembelo

Yayıncı:

Istanbul University

Ana Başlıklar:

Pharmacy Management

Dergi:

İstanbul Journal of Pharmacy Vol.55 Issue 1, pp.10-18

Belge Tipi:

Makale

Yayın Tarihi:

7/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001353993

pISSN:

2587-2087